Bill Anderson, Roche pharma chief (David Paul Morris/Bloomberg via Getty Images)

Roche trims out some pipeline fail­ures while flag­ging a PhI­II flop for Tecen­triq

Roche flagged a key set­back for its late-stage pipeline to­day, say­ing their IM­mo­tion010 kid­ney can­cer ad­ju­vant study of Tecen­triq has failed.

Roche phar­ma chief Bill An­der­son told an­a­lysts in the Q2 call to­day that the drug flopped on the pri­ma­ry end­point of dis­ease-free sur­vival, es­sen­tial­ly elim­i­nat­ing any up­side here for a fran­chise that earned $1.8 bil­lion in the first half of the year, up 11% over the same pe­ri­od in 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.